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Abstract
Background: Adiponectin is an adipokine possessing beneficial effects on obesity-related medical complications. A negative
association of adiponectin levels with breast cancer development has been demonstrated. However, the precise role of
adiponectin deficiency in mammary carcinogenesis remains elusive.
Methodology/Principal Findings: In the present study, MMTV-polyomavirus middle T antigen (MMTV-PyVT) transgenic
mice with reduced adiponectin expressions were established and the stromal effects of adiponectin haploinsufficiency on
mammary tumor development evaluated. In mice from both FVB/N and C57BL/6J backgrounds, insufficient adiponectin
production promoted mammary tumor onset and development. A distinctive basal-like subtype of tumors, with a more
aggressive phenotype, was derived from adiponectin haplodeficient MMTV-PyVT mice. Comparing with those from control
MMTV-PyVT mice, the isolated mammary tumor cells showed enhanced tumor progression in re-implanted nude mice,
accelerated proliferation in primary cultures, and hyperactivated phosphatidylinositol-3-kinase (PI3K)/Akt/beta-catenin
signaling, which at least partly attributed to the decreased phosphatase and tensin homolog (PTEN) activities. Further
analysis revealed that PTEN was inactivated by a redox-regulated mechanism. Increased association of PTEN-thioredoxin
complexes was detected in tumors derived from mice with reduced adiponectin levels. The activities of thioredoxin (Trx1)
and thioredoxin reductase (TrxR1) were significantly elevated, whereas treatment with either curcumin, an irreversible
inhibitor of TrxR1, or adiponectin largely attenuated their activities and resulted in the re-activation of PTEN in these tumor
cells. Moreover, adiponectin could inhibit TrxR1 promoter-mediated transcription and restore the mRNA expressions of
TrxR1.
Conclusion: Adiponectin haploinsufficiency facilitated mammary tumorigenesis by down-regulation of PTEN activity and
activation of PI3K/Akt signalling pathway through a mechanism involving Trx1/TrxR1 redox regulations.
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Introduction
The prevalence of obesity and obesity-related cancers has risen
alarmingly for the past several decades [1,2,3]. Unfortunately, the
mechanisms underlying the association between obesity and
cancer are not well understood. Recent evidences suggest that
adipokines, referring to a group of secreted factors from adipose
tissue, could be the key players in regulating obesity-related
carcinogenesis [4,5,6,7]. Adiponectin is an abundant adipocyte-
derived hormone that can elicit pleiotropic beneficial functions
against obesity-related medical conditions, such as diabetes,
chronic inflammation, atherosclerosis and tumorigenesis [8,9].
Decreased circulating concentrations of adiponectin are associated
with many obesity-related cancer diseases, including breast cancer,
endometrial cancer, gastric cancer, colorectal cancer, renal cell
carcinoma and prostate cancer [10,11,12,13,14,15,16]. Breast
cancer represents the second leading cause of death among
women. An inverse correlation of circulating adiponectin levels
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with breast cancer risk has been observed in both pre- and post-
menopausal women, independent of body mass index and other
known risk factors [17,18,19,20,21,22,23,24]. Moreover, mam-
mary tumors arising in women with low serum adiponectin levels
are more likely to show a biologically aggressive and poor
prognosis phenotype. These epidemiological evidences suggest
that reduced adiponectin expression might be causally involved in
obesity-related carcinogenesis.
In line with these clinical findings, numerous experimental
evidences support the role of adiponectin as an inhibitory factor
for breast cancer development [25,26,27,28,29,30,31,32,33].
Adiponectin at physiological concentrations suppresses the prolif-
eration and causes cell cycle arrest in both estrogen receptor (ER)-
negative and ER-positive human breast carcinoma cells. It inhibits
insulin- and growth factors-stimulated growth of ER-positive
breast cancer cells [28]. Adiponectin replenishment suppresses
mammary tumorigenesis of MDA-MB-231 cells in nude mice
[28]. Cell-type dependent signalling mechanisms have been
suggested to mediate the growth inhibitory effects of adiponectin.
In MCF-7 cells, adiponectin induces AMP-activated protein
kinase (AMPK) phosphorylation and inactivates p42/p44 MAPki-
nase (ERK1/2) [29]. By contrast, the inhibitory effects of
adiponectin on T47D cell growth are associated with inactivation
of ERK1/2 but not AMPK or p38 MAPK [18,28]. In MDA-MB-
231 cells with ectopic ER over-expression, globular adiponectin
inhibits cell proliferation by blocking JNK2 signalling [26]. In ER-
negative MDA-MB-231 cells, adiponectin could modulate the
glycogen synthase kinase-3beta (GSK3beta)/beta-catenin signal-
ing pathway [28]. Prolonged treatment with adiponectin markedly
reduces serum-induced phosphorylation of GSK3beta, decreases
intracellular accumulation and nuclear translocation of beta-
catenin, and suppresses cyclin D1 expression. Despite of these
progresses, whether adiponectin deficiency is a direct contributor
to the pathogenesis of breast cancer remain elusive.
In this study, we investigated the effects of reduced adiponectin
expression on mammary tumor development in MMTV-PyVT
transgenic mice. Mice with reduced adiponectin expressions were
established in both FVB/N and C57BL/6J backgrounds.
Adiponectin haploinsufficiency significantly reduced tumor latency
and promoted mammary tumor development in both female and
male animals. The results demonstrated that inadequate adipo-
nectin production might alter the stromal microenvironment
towards more pro-proliferative and pro-tumorigenic in mammary
tissue, by triggering the abnormal redox activities that led to the
inhibition of tumor suppressor PTEN and hyperactivation of
PI3K/Akt signaling pathways in mammary tumor cells.
Results
Adiponectin haploinsufficiency promotes mammary
tumor development in MMTV-PyVT mice
We generated MMTV-PyVT transgenic mice with reduced
adiponectin expressions in both FVB/N and C57BL/6J back-
grounds. PyVT transgenic mice with complete loss of the
adiponectin alleles could not be born alive across all generations
due to embryonic lethality. On the other hand, the knockout
genotypes were found in male and female PyVT(2/2) litters.
Therefore, mice with normal PyVT(+/2)/ADN(+/+) and reduced
PyVT(+/2)/ADN(+/2) adiponectin expressions were used in the
present study. The heterozygotes showed a 4–5 folds reduction of
adiponectin levels (Figure 1), which were more relevant to those
breast cancer patients with decreased adiponectin levels. Tumor
development of these mice was closely monitored every 2–3 days.
All mice carrying the PyVT transgene developed mammary
tumors. Tumor onset was recorded as the age of the animal at
which palpable abnormal masses were detected (Figure 2). The
overall median age of tumor latency in PyVT(+/2)/ADN(+/2)
mice of FVB/N background were 58 days for female (n = 20) and
115 days for male (n = 23) mice respectively, which were
significantly earlier than those of PyVT(+/2)/ADN(+/+) mice
(66 days for female and 133.5 days for male mice, n = 23 and 24
respectively, p,0.0001). Similar phenomena were also observed in
mice of C57BL/6J background. The overall median tumor latency
of female and male adiponectin haplodeficient PyVT mice (66 and
114 days respectively, n = 19) was significantly reduced comparing
with those of mice having normal adiponectin expression levels (73
and 137 days respectively, n = 19, p,0.0001). Tumor develop-
ment was monitored twice per week up to 14 and 28 weeks for
female and male mice respectively (Figure 3). No tumors were
found in PyVT(2/2) mice up to 60 weeks, irrespective of their
adiponectin levels. Tumor growth was significantly accelerated in
both female and male adiponectin haplodeficient PyVT mice
compared to PyVT(+/2)/ADN(+/+) mice. At the time of sacrifice,
the total wet weights of tumors in PyVT(+/2)/ADN(+/2) mice
was over 2-fold heavier than those with normal adiponectin
expression levels (Table 1). The mean tumor weight of female
PyVT mice of FVB/N background when sacrificed at 14 wks of
age was 9.88963.189 g in ADN(+/2) animals compared to
4.48361.645 g in ADN(+/+) animals. Similarly, in male FVB/N
PyVT mice sacrificed at 22 wks of age, the mean tumor weight
was 6.85761.262 g in ADN(+/2) animals compared to that of
3.68761.483 g in ADN(+/+) animals. On the other hand,
although the wet weights of lung tissues in female and male
PyVT(+/2) mice were heavier than those in non-transgenic
PyVT(2/2) mice (data not shown), they were not significantly
different between mice with reduced and normal adiponectin
expressions.
Distinct basal-like subtype of tumors in adiponectin
haplodeficient PyVT mice
Five subtypes of breast carcinoma with different outcomes,
including luminal A, luminal B, HER2+/ER2, basal-like and
normal breast-like, were revealed by microarray studies [42].
Luminal A and B are ER positive tumors, whereas the other three
subtypes are ER negative. Our preliminary microarray analysis
suggested that the molecular profiles of tumor cells derived from
PyVT(+/2)/ADN(+/2) mice were very different from those of
PyVT(+/2)/ADN(+/+) mice and could be clustered separately
(data not shown). To further validate such an observation, gene
markers associated with different tumor subtypes were quantified
by real-time PCR analysis. In PyVT(+/2)/ADN(+/2) tumors,
basal-like subtype genes, including KRT17, KRT5, MFGE8 and
FZD7, were significantly up-regulated, whereas HER2+/ER2
subtype-related genes, ERBB2 and MED1, were dramatically
down-regulated (Figure 4A). Histological analysis demonstrated
typical morphologic features associated with the basal-like subtype,
including markedly elevated geographic tumor necrosis, ribbon-
like architecture associated with central necrosis, pushing margin
of invasion, and stromal lymphocytic response in tumors from
PyVT(+/2)/ADN(+/2) mice [43] (Figure 4B). We could not
detect these morphological features in any of PyVT(+/2)/ADN(+/
+) mice or the original PyVT mice, which in contrast showed a
well-structured and organized morphology, suggesting that the
phenotype differences may not be tumor developmental stage
dependent. Moreover, the protein levels of p53, a characteristic
associated with tumors overexpressing ERBB2, was significantly
higher in the PyVT(+/2)/ADN(+/+) tumors comparing with
PyVT(+/2)/ADN(+/2) tumors (Figure 4C). These and the above
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evidence suggested that adiponectin deficiency might result in the
development of a basal-like subtype tumor, which could be
aroused from a different origin or subgroups of stem cells that
developed tumor more aggressively.
Accelerated growth of primary tumor cells derived from
adiponectin haplodeficient mice
We next isolated the primary tumor cells from the PyVT mice,
and examined their tumor development in athymic nude mice
following the protocol described previously [39]. Since tumors
originated from different torso regions of PyVT mice might show
various degrees of aggressiveness and onset latencies, we collected
only tumors from the axillary mammary glands and re-implanted
the isolated tumor cells into the posterior glands of athymic nude
mouse by intraductal inoculation. The transplantation was
reproducible and tumor growth rate correlated with the number
of transplanted cells. Consistent with those observed in PyVT
mice, the tumor development of cells derived from adiponectin
haplodeficient mice was more aggressive than those from mice
with normal adiponectin expressions (Figure 5, A and B). The
accelerated tumor growth was reproducibly observed even when
the cells were re-implanted for multiple times in new batches of
nude mice (data not shown), suggesting that serial transplantation
preserved the molecular characteristics of the tumor origin. At the
time of sacrifice, the total weights of the collected tumors from
PyVT(+/2)/ADN(+/2) mice were heavier than those of PyVT(+/
2)/ADN(+/+) mice (Table 2). Note that when the tumor cells
were exposed to physiological adiponectin secreted from adipo-
cytes in the mammary tissue of nude mice, the change in the
tumor volume was smaller, but still significantly different between
ADN(+/2) with ADN(+/+) groups. At ,3 weeks after tumor
occurrence, the measurable tumor volumes were 5.5 and 2.8 fold
higher in FVB/N male and female PyVT(+/2)/ADN(+/2)
animals respectively than those of PyVT(+/2)/ADN(+/+) mice
(Figure 3), whereas the differences for the implanted nude mice
were approximately 3.2 and 2.1 fold for male and female tumor
cells respectively (Figure 5). The results further suggest that the
magnitude of tumor growth could be suppressed in the presence of
endogenous expression of adiponectin by adipocytes. The lung
tissues of mice implanted with male tumor cells showed elevated
wet weights than those implanted with female tumor cells.
Moreover, there was a significant difference between the two
nude mice groups implanted with male PyVT(+/2)/ADN(+/+)
and PyVT(+/2)/ADN(+/2) tumor cells, with much higher lung
weights in the later group (Table 2). Massive lumps of metastatic
tumor mass could be seen on the surface of the lungs from nude
mice implanted with male PyVT(+/2)/ADN(+/2) tumor cells.
Hematoxylin and eosin staining confirmed that the metastatic
capacities of these tumor cells were much higher than those from
other groups (Figure 6).
We next compared the proliferation of the isolated primary
tumor cells in culture by using [3H]-thymidine incorporation assay
(Figure 5, C and D). Cells derived from PyVT(+/2)/ADN(+/2)
mice showed dramatically enhanced DNA synthesis under both
0.5% FBS and 10% FBS DMEM culture conditions. Moreover,
the fold changes of [3H]-thymidine incorporation between the two
time points (24 hr and 48 hr) in ADN(+/2) group were greater
than those of ADN(+/+) group. Similar results were also obtained
by crystal violet staining and cell number counting (data not
shown). These data demonstrated that tumor cells derived from
adiponectin haplodeficient mice were more aggressive, and their
intrinsic properties were well preserved even under conditions
without any hormonal interference.
Elevated PI3K/Akt/beta-catenin signalling in tumor cells
derived from adiponectin haplodeficient mice
We previously reported that chronic treatment of adiponectin
could modulate GSK3beta/beta-catenin pathway in MDA-MB-
Figure 1. Serum adiponectin distributions in wildtype and PyVT mice. The serum adiponectin concentrations were measured by an in-
house sandwich ELISA assay using blood samples collected from the tail vein of FVB/N and C57BL/6J mice. The median and mean values were
calculated and displayed in the table.
doi:10.1371/journal.pone.0004968.g001
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231 human breast cancer cells [28]. To investigate whether
adiponectin inadequacy could enhance beta-catenin signaling in
mammary tumors, we examined the phosphorylation status of
GSK3beta and its upstream protein kinase Akt, as well as the
protein levels and nuclear activities of beta-catenin (Figure 7A).
The results revealed that in primary tumor cells derived from
PyVT(+/2)/ADN(+/2) mice, phosphorylations of both Akt at
serine 473 and GSK3beta at serine 9 were significantly increased.
On the other hand, the phosphorylation of ERK1/2 was not
different between the two types of tumor cells from PyVT(+/2)/
ADN(+/+) and PyVT(+/2)/ADN(+/2) mice (data not shown).
The protein levels of beta-catenin and its target cyclin D1 were
largely elevated. The augmented beta-catenin signaling was also
confirmed by measuring its nuclear activities, which were
increased by ,4.5 folds in PyVT(+/2)/AND(+/2) tumor cells
according to the results from the TOPflash/FOPflash reporter
Figure 2. Reduced tumor latency in adiponectin haplodeficient MMTV-PyVT mice of both FVB/N and C57BL/6J genetic
backgrounds. The tumor onset was closely monitored by visual inspection and palpation every 2–3 days. Latency of mammary tumors was defined
as the age when a palpable lump was first detected in the mammary gland. Kaplan-Meier estimates of the tumor-free survival curves were calculated
and plotted. Median value represents the time point when 50% of animals developed palpable tumor masses. The significance of differences in
latency was analyzed by the Log-rank test. The comparisons were performed between ADN(+/+) and ADN(+/2) female (left panel) and male (right
panel) animals in FVB/N and C57BL/6J genetic backgrounds. CI, confidence interval.
doi:10.1371/journal.pone.0004968.g002
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assays (Figure 7A). Inappropriate Akt activation can occur through
PI3K. We found that the protein levels of the p110alpha subunits
of PI3K, the main isoform involved in oncogenesis, were slightly
increased in PyVT(+/2)/ADN(+/2) tumor cells (data not shown).
Both general (LY294002) and selective pharmacological antago-
nists against different isoforms of p110 catalytic subunits
(p110alpha-selective inhibitor PIK75, p110beta-selective inhibitor
TGX221 and p110delta-selective inhibitor IC8714) [34] were
then used for testing their effects in cells isolated from PyVT(+/2)/
ADN(+/2) tumors. Treatment with either LY294002 or PIK75
led to significantly attenuated phosphorylations of Akt and
GSK3beta and more than 50% reductions of nuclear beta-catenin
activities, whereas treatment with IC8714 and TGX221 did not
have much impacts (Figure 7B). Similarly, treatment with a
specific inhibitor of Akt1 and Akt2 (Akti-1/2) significantly reduced
beta-catenin and cyclin-D1 expression levels and caused about 11-
fold decrease of nuclear beta-catenin activities (Figure 7C). To
further verify the involvement of PI3K and Akt in the accelerated
Figure 3. Accelerated mammary tumor development in adiponectin haplodeficient MMTV-PyVT mice. Tumor growth in PyVT(+/2)/
ADN(+/+) and PyVT(+/2)/ADN(+/2) mice were monitored starting from 6 and 11 wks, up to 14 and 28 wks for female (left panel) and male (right
panel) mice respectively. Tumor sizes were measured using vernier calipers and tumor volume calculated as described in Methods. Each group
contained 13–20 mice, and the mean tumor volume 6SD was presented.
doi:10.1371/journal.pone.0004968.g003
Table 1. Total wet weights of tumor and lung tissues collected from PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/2) mice in FVB/N
and C57BL/6J background.
FVB/N C57BL/6J
Female (14 weeks) Male (22 Weeks) Female (16 weeks) Male (26 Weeks)
ADN(+/+) (n = 20)
ADN(+/2)
(n =20) ADN(+/+) (n =13)
ADN(+/2)
(n = 18) ADN(+/+) (n = 13)
ADN(+/2)
(n =19) ADN(+/+) (n =18)
ADN(+/2)
(n = 18)
Tumor 4.48361.645 9.88963.189* 3.68761.483 6.85761.262* 3.60961.846 8.70462.742* 2.13461.253 5.07962.51*
Lung 0.20360.041 0.21360.0309 0.25260.005 0.28660.028 0.22560.085 0.21960.026 0.26660.018 0.29260.029
*p,0.05 vs the corresponding PyVT(+/2)/ADN(+/+) mice group.
doi:10.1371/journal.pone.0004968.t001
Adiponectin and Breast Cancer
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proliferation of tumor cells derived from PyVT (+/2)/ADN(+/2)
mice, their inhibitors were used for cell proliferation measurement
using [3H]-thymidine incorporation assay. Importantly, the
general inhibitor LY294002 and Akti-1/2 showed greater extent
of attenuation on the cell growth at all time points, whereas the
p110alpha-selective inhibitor PIK75 was more potent than the
other two inhibitors (Figure 7D), suggesting that blockade of PI3K
or Akt reversed the proliferative advantage of adiponectin
haplodeficient tumors. Adiponectin treatment significantly atten-
uated phosphorylations of Akt and GSK3beta and beta-catenin
protein levels and nuclear activities, as well as inhibited cell
proliferation to a greater extent in PyVT (+/2)/ADN(+/2) tumor
cells (Figure 8). On the other hand, it had little effects on
p110alpha levels. These results implicated that the activation of
PI3K/Akt pathway might contribute to the elevated beta-catenin
signalling cascades in adiponectin haplodeficient mammary
tumors.
Decreased PTEN activities caused by altered redox
environment in adiponectin haplodeficient PyVT tumors
PTEN is one of the most frequently mutated tumor suppressors
that can prevent the activation of the cell survival PI3K/Akt
signaling pathway [44]. In the absence of PTEN function, cells
exhibit elevated Akt activities. It has been reported that PTEN
could bind to Trx1 in the cytosol, resulting in a functional loss of
its lipid phosphatase and membrane binding activity [45].
Interestingly, PTEN activities were decreased by more than 50%
in PyVT (+/2)/ADN(+/2) tumor cells (Figure 9A), whereas its
total protein amount was not significantly different (Figure 9B).
The activities of both Trx1 and its upstream binding enzyme,
TrxR1, were augmented by nearly 40% in PyVT(+/2)/ADN(+/
2) tumor cells (Figure 9A). While the protein levels of Trx1 were
similar between PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/
2) tumors, the total amount of TrxR1 was increased in PyVT(+/
2)/ADN(+/2) tumor cells (Figure 8B). Surprisingly, co-immuno-
precipitation experiment revealed that the amounts of Trx1-bound
PTEN were dramatically increased in tumor cells derived from the
adiponectin haplodeficient PyVT(+/2) mice (Figure 9C). Treat-
ment with curcumin, an irreversible inhibitor of TrxR1 (40),
elevated PTEN activity by nearly 3 folds in PyVT(+/2)/ADN(+/
2) tumor cells, which was accompanied by the decreased activities
of both TrxR1 and Trx1 (Figure 9A). A stimulatory effect on
PTEN activity was also observed in cells treated with adiponectin
(Figure 9A). In PyVT(+/2)/ADN(+/2) tumor cells, the TrxR1
promoter-driven reporter activity was ,1.8 fold higher than that
of PyVT(+/2)/ADN(+/+) tumor cells (Figure 9D). Treatment with
adiponectin for 24 hrs significantly reduced the reporter activities
by ,60% in PyVT(+/2)/ADN(+/2) tumor cells but had no
significant effects on PyVT(+/2)/ADN(+/+) tumor cells. Similar
effects were also observed for TrxR1 mRNA levels in tumor cells
treated with or without adiponectin (Figure 9D). Taken together,
Figure 4. A basal-like subtype of mammary tumors derived from adiponectin haplodeficient MMTV-PyVT mice. A, Quantitative RT-PCR
analysis of the expression levels of gene markers associated with different subtypes of breast tumors. The RNA was extracted from cultured primary
tumor cells isolated from 14-week old PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/2) female FVB/N mice and quantitative PCR analysis performed as
described in the Methods. *, P,0.01 vs PyVT(+/2)/ADN(+/+) group, n = 10. B, Morphological features of tumors derived from 14-week old female
PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/2) mice of the FVB/N background. Distinct morphologies were observed between tumors collected from
mice with normal and reduced adiponectin levels. Note that central necrosis and geographic tumor necrosis, as well as stromal lymphocytic
responses represented the typical basal-like subtype of breast tumors in PyVT(+/2)/ADN(+/2) mice. C, The protein levels of p53 were much higher in
tumors derived from PyVT(+/2)/ADN(+/+) mice compared to those of the PyVT(+/2)/ADN(+/2) mice as measured by Western Blotting using specific
antibodies purchased from Cell Signaling Biotechnology.
doi:10.1371/journal.pone.0004968.g004
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these results suggested that in tumor cells derived from adiponectin
haplodeficient mice, the increased TrxR1/Trx1 redox activities
might be involved in inactivation of PTEN and hyperactivation of
PI3K/Akt signalling pathways.
Discussion
Although the anti-tumor activities of adiponectin have been
suggested by numerous clinical and experimental evidences, the
underlying mechanisms remain to be established. Here, we have
evaluated the impacts of reduced adiponectin expression on
mammary tumor development in MMTV-PyVT mice. Our
results demonstrate that in both FVB/N and C57BL/6J genetic
backgrounds, adiponectin inadequacy is associated with earlier
tumor onset and accelerated tumor growth (Figure 2, Figure 3
and Table 1). The aggressive phenotypes of tumor cells derived
from PyVT(+/2)/ADN(+/2) mice are retained during serial
trans-implantations in nude mice as well as multiple passages in
culture (Figure 5), suggesting that insufficient adiponectin
production from adipose tissue might result in an abnormal
microenvironment that leads to distinct but permanent genetic
and phenotypic modifications of mammary epithelial cells.
Indeed, both histological and gene expression analyses suggest a
distinct basal-like subtype of tumors in PyVT(+/2)/ADN(+/2)
mice (Figure 4). Tumor cells derived from adiponectin haplodefi-
cient mice show enhanced beta-catenin nuclear activities and
protein stabilities, which might be partly attributed to the
hyperactivated PI3K/Akt signaling (Figure 7). While adiponectin
treatment restores most of the changes downstream of PI3K,
including Akt and GSK3beta and beta-catenin, it has little effects
on p110alpha (Figure 8). On the other hand, adiponectin
deficiency causes inactivation of PTEN and results in the
hyper-activated PI3K/Akt signaling in PyVT(+/2)/ADN(+/2)
tumors (Figure 9).
Figure 5. Mammary tumor cells derived from adiponectin haplodeficient mice were more aggressive. Primary mammary tumor cells
were isolated from FVB/N PyVT mice with normal [PyVT(+/2)/ADN(+/+)] or reduced [PyVT(+/2)/ADN(+/2)] adiponectin expressions, and implanted
into nude mice for assessing their tumor development in vivo (A and B), or subjected to culture and [3H]-thymidine incorporation assays for
evaluating their proliferations in vitro (C and D). The comparison between PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/2) groups were performed for
tumor cells derived from both female (A and C) and male (B and D) mice. Tumor growth was presented as the fold changes of tumor volume against
the first measurement at day 4 (A and B). DNA synthesis was monitored in 0.5% and 10% FBS culture conditions at 24 and 48 hrs after seeding (C and
D). CPM, counts per minute. *, P,0.05 and **, P,0.01 vs corresponding groups (n = 13–18).
doi:10.1371/journal.pone.0004968.g005
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PTEN/PI3K/Akt constitutes an important pathway regulating
the signaling of multiple biological processes such as apoptosis,
metabolism and cell proliferation [46]. PTEN activity is lost by
mutations, deletions, promoter methylation silencing, or protein
modifications at high frequency in many primary and metastatic
human cancers [47]. Hyperactivation of the PI3K/Akt signaling
pathway triggered by PTEN inactivation has been found to
correlate with increased breast cancer risks, poor prognosis and
resistance to hormone therapy [44]. In adiponectin haplodeficient
PyVT tumors, while the total protein levels of PTEN are not
altered, its activities are significantly decreased (Figure 9). PTEN is
well-known to be regulated by the redox state of the active site
cysteine residues [48]. Oxidation of PTEN resulted from thiol
modification leads to reversible inhibition of its phosphatase
activity. The thioredoxin system, composed of TrxR, Trx, and
NADPH, represents one of the main thiol-dependent electron
donor systems and plays critical roles in the regulation of the
cellular redox environment [49]. Although the reduction of
oxidized PTEN appears to be dominantly mediated by Trx, it
has been reported that Trx1 inhibits its phosphatase activity by
binding in a redox dependent manner to PTEN through disulfide
bond formation [45]. Moreover, knocking out of thioredoxin-
interacting protein, an inhibitor of Trx NADPH-dependent
reduction of PTEN, causes accumulation of oxidized PTEN and
elevated Akt phosphorylation [50]. We find that there is a
significantly augmented formation of Trx1-PTEN complexes in
tumor cells derived from adiponectin haplodeficient PyVT mice,
possibly due to elevated TrxR1 and Trx1 activities (Figure 9A).
Adiponectin treatment decreases TrxR1 promoter-mediated
transcription and its mRNA levels, which are highly upregulated
in adiponectin haplodeficient tumors (Figure 9D). These results
suggest that adiponectin might regulate PTEN activities through
Table 2. Total net weights (g) of tumor and lung tissues collected from nude mice implanted with primary tumor cells isolated
from female and male PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/2) mice.
Nude mice
Female (18 days after implantation) Male (24 days after implantation)
ADN (+/+) (n = 17) ADN (+/2) (n = 13) ADN (+/+) (n =13) ADN (+/2) (n =18)
Tumor 0.50360.262 0.87560.693* 0.44960.366 0.83160.425*
Lungs 0.16060.063 0.17460.014 0.18760.0407 0.24860.0928*
*p,0.05 vs the corresponding PyVT(+/2)/ADN(+/+) mice group.
doi:10.1371/journal.pone.0004968.t002
Figure 6. Tumor cells derived from male PyVT(+/2)/ADN(+/2) mice show increased metastatic capacities in nude mice comparing
with those of PyVT(+/2)/ADN(+/+) mice. Both hematoxylin and eosin staining (upper panel) and the morphological evaluations (bottom panel)
were performed to evaluate metastasis of the lung tissues.
doi:10.1371/journal.pone.0004968.g006
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Trx/TrxR redox system, and an altered Trx/TrxR redox balance
could play important roles in promoting tumorigenesis in PyVT(+/
2)/ADN(+/2) mice.
In this study, we have shown that inhibition of both PI3K and
Akt results in a reduced nuclear beta-catenin activities and protein
stabilities, supporting the involvement of PI3K/Akt pathway in the
Figure 7. Hyperactivation of Akt/GSK3beta/beta-catenin signaling in adiponectin haplodeficient tumors. A, Components of the PI3K/
Akt/beta-catenin axis were characterized in the tumor cell lysates by Western blotting (upper panel) and nuclear beta-catenin activities analyzed
using a TOPflash/FOPflash luciferase reporter assay (bottom panel). Results were expressed as fold changes relative to the values of samples derived
from PyVT(+/2)/ADN(+/+) cells. #, P,0.01 vs PyVT(+/2)/ADN(+/+) group (n = 6). B, Various pharmacological inhibitors, including LY294002 for PI3K,
PIK-75 for p110alpha, TGX221 for p110beta and IC8714 for p110delta, were used for the treatment of PyVT(+/2)/ADN(+/2) tumor cells at the
concentration of 1026 M. The phosphorylations of Akt (pAkt), GSK3beta (pGSK3beta), and beta-catenin (pBeta-catenin), as well as their total levels in
the cell samples treated with each specific inhibitor for 30 min were analyzed by Western Blotting (upper panel). After 24 hr incubation, the nuclear
beta-catenin activities were evaluated using the TOPflash/FOPflash reporter assay (bottom panel). *, P,0.01 vs vehicle (n = 4). C, Primary tumor cells
isolated from PyVT(+/2)/ADN(+/2)mice were cultured and treated without (vehicle) or with 1026 M of specific inhibitor of Akt-1/Akt-2 isoforms (Akti-
1/2) for 24 hr. Protein levels of phosphorylated Akt (pAkt), beta-catenin, and cyclinD1 in the cell lysates were analyzed by Western Blotting (upper
panel) and the nuclear beta-catenin activities measured using a TOPflash/FOPflash luciferase reporter system (bottom panel). *, P,0.01 vs vehicle
control (n = 3). D, Evaluation of the effects of various inhibitors on cell proliferation by [3H]-thymidine incorporation assay. CPM, counts per minute. *,
P,0.01 vs vehicle in each treatment group (n = 5). Results were derived from three independent experiments.
doi:10.1371/journal.pone.0004968.g007
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hyper-activation of beta-catenin signalling associated with adipo-
nectin haplodeficient tumors (Figure 7). Notably, the cross-talks
between PI3K/Akt and the canonical Wnt/beta-catenin signaling
pathways have been demonstrated by a number of studies from
independent groups (23). Overexpression of PTEN inhibits Wnt-1
induced beta-catenin stabilization and mammary tumorigenesis in
mice [51]. PI3K/Akt pathway is involved in Wnt3a-induced
proliferation and beta-catenin nuclear accumulation in NIH3T3
cells [52]. In HT29 colorectal adenocarcinoma cells, inhibition of
PI3K was accompanied by a considerably reduced expression level
of beta-catenin [53]. The linkage between Wnts and PI3K/Akt
signalling have also been found in the regulation of bone mass,
osteoblast progenitor proliferation, differentiation and osteoblast
apoptosis, as well as cardiomyogenesis [54]. The protein levels of
p110alpha subunits are elevated in tumor cells isolated from
adiponectin haplodeficient PyVT mice. However, adiponectin
treatment has no effects on p110alpha, despite that it can inhibit
Akt phosphorylation and nuclear beta-catenin activities (Figure 7),
suggesting that the inhibitory effects of this hormone is
downstream of PI3K and upstream of Akt, possibly through
modulating PTEN’s activities.
Insufficiency in adiponectin production might promote mam-
mary tumor formation from distinct type of cells, as suggested by
the consistent morphological and gene expression differences
between tumors derived from PyVT(+/2)/ADN(+/+) and
PyVT(+/2)/ADN(+/2) mice (Figure 3). Adiponectin haplodefi-
cient tumor is more related to a basal-like subtype, which is
characterized by high proliferative activity and unfavorable
Figure 8. Tumor cells derived from PyVT(+/2)/ADN(+/2) mice showed increased sensitivity to adiponectin-mediated inhibition of
Akt/GSK3beta/beta-catenin signaling and cell proliferation. Tumor cells isolated from both PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/2)
mice were pre-treated with 15 mg/ml of adiponectin for 24 hr in 0.5% FBS DMEM. The serum-stimulated phosphorylation changes of Akt, GSK3beta
and beta-catenin were analyzed by Western Blotting (A) as described previously [28]. The nuclear beta-catenin activities were assayed using the
TOPflash/FOPflash reporter assay (B). Cell proliferation was evaluated for both types of tumor cells under the indicated treatment conditions using 3H-
thymidine incorporation assay (C). *, P,0.05 and **, P,0.01 vs corresponding vehicle control (n = 3, from three independent experiments).
doi:10.1371/journal.pone.0004968.g008
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prognosis. The origin of this subtype tumor is unclear, but
suggested to be the basal/myoepithelial cells, derived from
epithelial-to-mesenchymal transition as a result of dedifferentia-
tion, or from stem cells [43]. It will be interesting to investigate
which types of tumor cell transformation could be facilitated by
the altered microenvironment associated with adiponectin
haploinsufficiency. It has long been noticed that cancer cells
exhibit increased glycolysis for ATP production due, in part, to
respiration injury (the Warburg effect). The increase in NADH
caused by respiratory deficiency inactivates PTEN through a
redox modification mechanism, leading to Akt activation. Our
group has recently reported that adiponectin deficiency leads to
dysregulated mitochondrial functions, which result in decreased
activities of the respiratory chain and subsequent accumulation of
reactive oxygen species [55]. We have also found that
adiponectin can modulate redox-regulated transcription factor
Sp1 activities [56]. Interestingly, the expression of both Trx1 and
TrxR1 can be regulated by Sp1 [57]. Whether these mechanisms
contribute to the dysregulated Trx/TrxR redox system in
adiponectin insufficiency-related carcinogenesis are currently
under investigation in our laboratory. Nevertheless, these findings
might provide a novel mechanistic insight to explain how
metabolic alteration in adiponectin haplodeficient tumor may
gain a survival advantage.
Figure 9. Inactivation of PTEN was at least partially caused by the augmented Trx1/TrxR1 redox activities in PyVT(+/2)/ADN(+/2)
tumor cells. A, activities of PTEN, TrxR1 and Trx were evaluated in the lysates derived from PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/2) tumor cells
using colorimetric assays. Briefly, cells were treated with vehicle control (CON), 10 mM curcumin (CUR) or 15 mg/ml adiponectin (ADN) for 24 hrs.
Immunoprecipitation and phosphatase assay were performed as described in Methods. Results were expressed as fold changes relative to the
enzyme activities in PyVT(+/2)/ADN(+/+) tumor cells treated with vehicle control. B, total protein levels of PTEN, TrxR1 and Trx1 in cell lysates from
PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/2) tumors were analyzed by Western Blotting. C, co-immunoprecipitations were performed with the
specific antibodies against PTEN or Trx1 in both PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/2) tumor cell lysates. The immune-complexes were
analyzed by SDS-PAGE and Western Blotting using antibodies as indicated. D, intrinsic transcriptional activities of TrxR1 promoter (left panel) and the
mRNA levels of TrxR1 and Trx1 (right panel) were evaluated in PyVT(+/2)/ADN(+/+) and PyVT(+/2)/ADN(+/2) tumor cells treated without (CON) or
with adiponectin (ADN, 15 mg/ml) using TrxR1 reporter assay (left panel) and quantitative RT-PCR respectively (right panel). *, P,0.05 vs PyVT(+/2)/
ADN(+/+) cell control; #, P,0.05 vs PyVT(+/2)/ADN(+/2) cell control (n = 3, from three independent experiments).
doi:10.1371/journal.pone.0004968.g009
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Materials and Methods
Materials
Antibodies against PI3K p110-alpha (#4255), PI3K p85
(#4292), phospho-Akt (Ser473) (#9271), Akt (#9272), GSK3beta
(#9315), phospho-GSK3beta (Ser9) (#9336) and phospho-beta-
catenin (Ser33/37/Thr41) (#9561) were obtained from Cell
Signaling Biotechnology (Beverly, MA). Anti-Trx1 (sc-20146),
anti-TrxR1 (sc-28321), and anti-beta actin (sc-1615) antibodies
were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
PTEN (MAB4037) was from Chemicon International, Inc.
(Temecula, CA), anti-Cyclin D1 (CC12) was from CalBiochem-
Novachem Crop. (San Diego, CA), and sheep anti-beta-catenin
was from Symansis (Auckland, New Zealand). Pharmacological
inhibitors, including Akt-1/2 inhibitor, PI3K p110alpha inhibitor
PIK-75, PI3K p110beta inhibitor TGX221, and PI3K p110delta
inhibitor IC87114 were provided by Dr Peter R. Shepherd
[34,35]. The general PI3K inhibitor, LY294002, was from Cell
Signaling Biotechnology. ImProm-IITM Reverse Transcription
System and Bright-GloTM luciferase assay system were from
Promega (Madison, WI). TOP/FOPflash (T-cell factor-lymphoid
enhancer factor-1 (TCF-LEF) reporter plasmid) was from Upstate
(Lake Plasid, NY). pGL-TrxR1 reporter plasmid was generated by
cloning the proximal promoter of the human TrxR1 gene using
the GenomeWalker kit from Clontech (Palo Alto, CA). The
human TrxR1 and Trx1 were purchased from Sigma. The rat
TrxR1 was purified from rat liver according to published
procedure [36] and the purity confirmed by mass spectrometry
analysis. Unless specified, all chemicals were obtained from Sigma-
Aldrich Co. (St Louis, MO). Recombinant full length adiponectin
(ADN) was produced as we described previously [28].
Establishment of the MMTV-PyVT transgenic mice
haplodeficient in adiponectin expression
FVB/N-Tg(MMTV-PyVT)634Mul/J transgenic mice were
obtained from the Jackson Laboratory (Bar Harbor, Maine)
[37]. Since the female PyVT transgenic mice were defective in
litter delivery and lactation, all breedings were carried out using
male PyVT transgenic mice. The male heterozygote PyVT(+/2)
mice were cross-bred with female adiponectin knockout mice [38]
and back-crossed for at least 12 generations to obtain mice with
reduced adiponectin expression in both C57BL/6J and FVB/N
backgrounds. The genotype was verified by PCR analysis of their
genomic DNA using primers listed in Table 3. In addition, serum
adiponectin levels were monitored using an in-house ELISA, with
the standard curve generated from known concentrations of
recombinant adiponectin. Note that mice with the genotype of
PyVT(+/2)/ADN(2/2) (transgenic PyVT with adiponectin null
alleles) could not be found in all generations of alive litters, which
included over 800 mice. On the other hand, their embryos were
found to be dead at the early stage of foetal development. As a
consequence, the sizes of litters with abnormal adiponectin
expressions (3–5) were consistently smaller when compared to
those of control PyVT breeding pairs (8–10). Therefore, the PyVT
transgenic mice with adiponectin deficiency were referred to those
with PyVT(+/2)/ADN(+/2) genotypes in this study. The
circulating levels of adiponectin in PyVT(+/2)/ADN(+/2)
FVB/N and C57BL/6J mice range from 3–15 mg/ml and 0.2–
5 mg/ml respectively, whereas PyVT(+/2)/ADN(+/+) mice in
both FVB/N and C57BL/6J background have a much higher
adiponectin level of over 20 mg/ml and 10 mg/ml respectively,
with the median values increased by 4–5 folds. Tumor
development was closely monitored every 2–3 days. Tumor
latency was recorded as the age of mice when palpable tumors
were first detected in at least one of the ten mammary fat pads.
Tumor sizes were measured using digital vernier calipers and
tumor volume calculated using the formula [sagittal dimension
(mm)6(cross dimension (mm)2] / 2 and expressed in mm3. All
animal experimental protocols were approved by the Animal
Ethics Committee at the University of Hong Kong and their care
was in accord with the institution guidelines.
Sandwich ELISA for murine adiponectin
The anti-murine adiponectin monoclonal antibody was bioti-
nylated with a kit from Pierce, and free biotin was removed by
dialysis. The polyclonal anti-murine adiponectin antibody was
diluted to a concentration of 2 mg/ml, added to each well of a
microtiter plate, and incubated overnight at 4 uC. The coated
plate was washed 3 times with PBS containing 1% bovine serum
albumin and blocked with 100 ml of PBS containing 1% bovine
serum albumin and 0.05% Tween for 2 h. Mouse serum was
diluted 1:10000, and 100 ml of the diluted samples were applied to
each well along with the standard, incubated at 37 uC for 1 h,
washed 3 times with PBS-Tween, and then incubated with 100 ml
of the biotinylated monoclonal antibody (2 mg/ml) for another
2 h. After washing 3 times, the wells were incubated with
streptavidin-conjugated horseradish peroxidase for 60 min and
subsequently reacted with tetramethylbenzidine reagent for
15 min. 100 ml of 2 M H2SO4 was added to each well to stop
the reaction, and the absorbance at 450 nm was measured. The
intra- and interassay coefficients of variance were determined by
measuring five plasma samples in a total of six independent assays
with duplicate determinations.
Primary tumor cell isolation, culture and re-implantation
Primary cell isolation was performed as described previously
with slight modifications [39]. Briefly, aseptically collected tumors
from PyVT mice were mechanically minced, passaged through a
100-mm sterile nylon cell strainer (BD Falcon) and suspended in
serum-free high glucose DMEM. Cells were further dissociated by
serial passaging through a syringe with 25-gauge needles. After
brief centrifugation at 1,000 r.p.m for 5 minutes to remove dead
cell debris and the low-density stromal cells, the cell pellets were
resuspended for viable cell counting using 0.4% trypan blue. 106 of
isolated primary tumor cells were implanted into the third right
mammary fat pad of female athymic nu/nu mice (4–6 weeks) by
intraductal injection. Tumor development was monitored every 3–
4 days using caliper measurements (in millimeters) in two
perpendicular dimensions (length and width). Tumor volumes
were calculated as described above.
Co-immunoprecipitation and Western Blotting
Isolated tumor tissues were homogenized in RIPA buffer
[50 mM Tris-HCl, pH 7.4; 1 mM EDTA; 150 mM NaCl; 1%
Nonidel P40; 1% Triton X-100; 0.5% deoxycholic acid sodium
salt; 1 mM NaF; 1 mM sodium orthovanadate; and complete
protease inhibitor cocktail (Roche Applied Science, IN)] on ice
and centrifuged for 5 min at 14,000 r.p.m to remove large debris.
Protein concentration of the supernatant was determined by a
BCA Protein Reagent Kit (Pierce Biotechnology, Rockford, IL).
Five hundred micrograms of the total cell lysates were firstly
incubated with rabbit IgG for 30 minutes, pre-cleared with 50 ml
of protein G-Sepharose beads (Pierce Biotechnology, Rockford,
IL), and then incubated with two micrograms of either Anti-Trx1
or Anti-PTEN antibody overnight at 4uC. 50 ml of protein G-
Sepharose beads was added and incubated for 2 hrs at 4uC. Beads
bound with immune complexes were collected by centrifugation
and washed twice prior to elution into 90 ml of buffer containing
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0.2 M Glycine-HCl, pH 2.5, which was neutralized with 10 ml of
neutralization buffer (1 M Tris-HCl, pH 9.0). The elutants were
subjected to 15% SDS-PAGE and Western blotting analysis, or
enzyme activity measurement as described below.
For Western Blotting, fifty micrograms of proteins derived from
cell or tissue lysates were separated by SDS-PAGE and transferred
to polyvinylidene difluoride membranes. Following blocking,
membranes were probed with various primary antibodies to
determine different levels of protein expressions. Immunoreactive
antibody-antigen complexes were visualized with the enhanced
chemiluminescence reagents from GE Healthcare (Uppsala,
Sweden).
[3H]-thymidine incorporation assay for cell proliferation
measurement
56104 of isolated primary tumor cells were seeded into each of
the 24-well culture plate and allowed a period of at least 24 hours
for cell settlement and attachment. After being treated under
different conditions, 1 mCi/ml of [3H-methyl] thymidine was
added into each well for 6 hours of incorporation. At the end of
experiment, the culture media were removed and cells washed
twice with cold PBS. DNA was precipitated with 0.5%
trichloroacetic acid for 30 min. Air-dried precipitates were then
solubilized with 0.2 mol/l NaOH, neutralized with 0.2 mol/l
HCl, and incorporated [3H]-thymidine was quantified with a
liquid scintillation counter (Backman LS6500).
Quantitative RT-PCR
Total RNA was isolated from primary tumor cells and used for
the synthesis of cDNA. Quantitative RT-PCR was performed
using SYBRH GreenERTM qPCR Supermix (Invitrogen, Carls-
bad, CA). The reactions were carried out on a 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA). Quan-
tification was achieved using Ct values that were normalized with
18S RNA as internal control. The primers were listed in Table 4.
Beta-catenin/T-cell factor-lymphoid enhancer factor-1
(TCF-LEF) and thioredoxin reductase 1 (TrxR1)
transcription reporter assay
Nuclear activities of endogenous beta-catenin were analyzed by
the TOPflash/FOPflash reporter system as described previously
[28]. To normalize transfection efficiency in the reporter assays,
cells were cotransfected with pRL-TK plasmid, which contains a
functional Renilla luciferase gene cloned downstream of a herpes
simplex virus thymidine kinase promoter (Promega, Madison, WI).
The luciferase reporter containing a human thioredoxin reductase
promoter region (from 2386 bp to +218 bp, pGL3-TR) was
constructed into a firefly-luciferase pGL3-basic Vector (Promega,
Madison, WI). The assay was carried out as described above with
the original unmodified pGL3-basic vector as a negative control.
Luminescence was measured using a Bright-GloTM Luciferase
Assay System (Promega, Madison, WI) on Lumat LB9507, and
normalized to control Renilla luciferase signal. Luciferase activity
was calculated against the negative control signals and fold
differences were compared among groups in separate assays.
Measurement of PTEN lipid phosphatase activities
The lipid phosphatase activity of PTEN was measured as
described previously with slight modifications [40]. Phosphatase
reactions were performed in 25 ml assay buffer (100 mM Tris-HCl
pH 8, 10 mM DTT, and 200 mM water-soluble diC8-PIP3) with
25 ml sample. PTEN proteins immunoprecipitated on protein G-
Sepharose beads (Pierce Biotechnology, Rockford, IL) were washed
twice in a low stringency buffer (20 mM HEPES, pH 7.7, 50 mM
NaCl, 0.1 mM EDTA and 2.5 mM MgCl2) and once in the
phosphatase assay buffer lacking PIP3. Reactions were done in a 96-
well plate with an incubation period of 40 minutes at 37uC. The
release of phosphate from the substrate was measured in a
colorimetric assay by using the Biomol Green Reagent in
accordance with the instructions of the manufacturer. The
absorbance at 620 nm was measured with a mQuant MQX200
microplate reader (Biotek Instruments, Inc., Highland Park, VT). A
standard curve was performed in each assay, and the amount of free
phosphate was calculated from the standard curve line-fit data.
Measurement of TrxR1 and Trx1 activities
The assays for measuring the activities of TrxR and Trx were
performed in 96-well plates using an insulin reduction endpoint assay
as described previously [41] with slight modification. For determi-
nation of TrxR1 activity, 25 mg of the primary tumor lysates were
mixed thoroughly with a 50 ml reaction buffer containing 55 mM
HEPES, pH 7.6, 0.02 mM insulin, 0.4 mMNADPH, 2 mMEDTA
and 2 mM human Trx1 in the mQuant MQX200 microplate reader
(Biotek Instruments, Inc). Reaction solutions without human Trx1
were used as the control. After performing a 20-min incubation at
37uC, 200 ml of 1 mM DTNB in 6 M guanidine hydrochloride
solutionwas added to stop the reaction. The free thiols of the reduced
insulin were determined by DTNB reduction, and the activity of
TrxR was represented as the absorbance at wavelength 412 nm,
where 1 mole of NADPH reduced 1 mole of disulfide, giving rise to 2
Table 3. List of primers used for genotyping.
Primer name NCBI GeneBank accession IDs Sequence range
Product
size (bp) Primer sequences
AdipoWT NT_039624 11673–12146 473 (F) 59- CCA GAG AAC AAC GAA CAA GGA- 39
(R) 59 – CGA ATG GGT ACA TTG GGA AC- 39
Neo User_PGKneobpA Sequence sequence 4575 bp DNA
circular SYN 08/24/2007
2950–3101 171 (F) 59 – TGA ATG AAC TGC AGG ACG AG- 39
(R) 59 – ATA CTT TCT CGG CAG GAG CA- 39
MMTV/PyVT J02288 881–1437 556 (F) 59- GGA AGC AAG TAC TTC ACA AGG G- 39
(R) 59- GGA AAG TCA CTA GGA GCA GGG- 39
Tcrd NG_007044 1715433–1715638 206 (F) 59- CAA ATG TTG CTT GTC TGG TG- 39
(R)59 GTC AGT CGA GTG CAC AGT TT- 39
doi:10.1371/journal.pone.0004968.t003
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mole of free TNB with the extinction coefficient 13.6 mM21 cm21.
For accessing the activity of Trx, assays were performed as above
with the similar reaction cocktail except that 600 nM rat TrxR1 but
not Trx1 was included. Reaction solutions without TrxR1 were used
as the control.
Data analysis and statistics
All experiments were performed with six to eight samples per
group, and all results were derived from at least three independent
experiments. Data are shown as mean values 6standard deviation
(SD). Comparison between groups was done using Student’s
unpaired t-test. Tumor latency was analysed using a Kaplan-
Meier survival analysis followed by log rank tests. In all statistical
comparisons, P,0.05 was used to indicate a significant difference.
Note that for the ex vivo and in vitro experiments, while tumor cells
derived from male and female mice showed similar characteristics
in both FVB/N and C57BL/6J backgrounds, only results derived
from the tumor cells of female FVB/N mice were shown.
Table 4. List of primers used for real time quantitative PCR analysis.
Gene name
Gene
symbol
Accession
IDs
Sequence
range
Product size
(bp) Primer sequences
Forkhead box A1 FOXA1 NM_008259 456–588 133 (F) 59-GAA GGG CTC CTG TGC TAG TT-39
(R) 59-AGG ACA TGT TGA AGG AAG CC-39
Protein tyrosine phosphatase 4a2 PTP4A2 NM_008974 427–598 172 (F) 59-GAA GGG CTC CTG TGC TAG TT-39
(R) 59-TGC CCA TTG GTA TCT CTG AA-39
c-mer proto-oncogene tyrosine kinase MERKT NM_008587 1944–2127 185 (F) 59-AAG CAG CAT GCA TGA AAG AC-39
(R) 59-TGC AGG TGA ATG TAC TTG GG-39
Estrogen receptor 1 (alpha) ESR1 NM_007956 1560–1752 193 (F) 59-CCG GAG TGT ACA CGT TTC TG-39
(R) 59-TTG TTA CTC ATG TGC CGG AT-39
ATP synthase, H+ transporting, mitochondrial
F0 complex, subunit c
ATP5G NM_007506 167–223 57 (F) 59-GGG AAT TCC AGA CCA GTG TC-39
(R) 59-TTG AGA GAT GGG TTC CTG GC-39
Cyclin E1 CCNE1 NM_007633 160–330 171 (F) 59-ACA GCT TCG GGT CTG AGT TC-39
(R) 59-GGC AAT TTC TTC ATC TGG GT-39
Peroxiredoxin 4 PREDX4 NM_016764 716–883 118 (F) 59-CGA TGA CAA AGG AGT CCT GA-39
(R) 59-GCT GGA TCT GGG ATT ATT GT-39
Keratin 17 KRT17 NM_010663 679–851 173 (F) 59-AAG AAG AAC CAC GAG GAG GA-39
(R) 59-AAG AAC CAG TCT TCG GCA TC-39
Keratin 5 KRT5 NM_027011 1005–1170 166 (F) 59-GCA GAC ACA CGT CTC TGA CA-39
(R) 59-TTG CAG CTC CTC ATA CTT GG-39
Milk fat globule-EGF factor 8 protein MFGE8 NM_001045489 278–444 167 (F) 59-AGA CTG AGA GAG GAC CAT GC-39
(R) 59-CAT GCC CAG CTG TGT AGA AC-39
Frizzled homolog 7 FZD7 NM_008057 1477–1631 155 (F) 59-TTC CTA GGT GAG CGT GAC TG-39
(R) 59-TAG GTG AGC ACC GTG AAG AG-39
Chemokine (C-X-C motif) ligand 1 CXCL1 NM_008176 179–352 174 (F) 59-ACC CAA ACC GAA GTC ATA GC-39
(R) 59-GTT GTC AGA AGC CAG CGT T-39
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 ERBB2 NM_001003817 2980–3162 183 (F) 59-ATT TGC TGG AGA AGG GAG AA-39
(R) 59-AGT CCT CGT TCT GGA TGA CC-39
Mediator complex subunit 1 MED1 NM_013634 1459–1623 165 (F) 59-CAG ACC TTG GAG TGA AAC CA-39
(R) 59-GAG CCC AGT CCA TTC TGT CT-39
Acyl-CoA synthase long-chain family member 1 ACSL1 NM_007981 1586–1759 174 (F) 59-CTA TGA AGG CTA CGG ACA GA-39
(R) 59-CCT TTC ACA CAC ACC TCA CC-39
Phosphatidylinositol 3-kinase, regulatory subunit,
polypeptide 1 (p85 alpha)
PIK3R1 NM_001077495 1906–2080 175 (F) 59-TCC AAA TAC CAG CAG GAT CA-39
(R) 59-ATG CTT CGA TAG CCG TTC TT-39
Thioredoxin reductase 1 TXNRD1 NM_00142523 1587–1763 177 (F) 59-TTG GAA TAT GGC TGT TGT GG-39
(R) 59-CAC GAC ACG TTC ATC GTC TT-39
Thioredoxin 1 TXN1 NM_011660 315–484 170 (F) 59-AAG CCC TTC TTC CAT TCC CT-39
(R) 59-CCT TGT TAG CAC CGG AGA AC-39
18S RNA RN18S NR_003278 1194–1294 101 (F) 59-TAA AGG AAT TGA CGG AAG GG-39
(R) 59-CTG TCA ATC CTG TCC GTG TC-39
doi:10.1371/journal.pone.0004968.t004
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